News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
US FDA Warns of Muscle Harm When Ingredients in Heart Drugs Merck & Co., Inc., Abbott Laboratories Combine
August 8, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Aug 8 (Reuters) - U.S. health officials warned the public on Friday about the risk of a rare type of muscle injury seen when the cholesterol drug simvastatin is combined with the anti-arrhythmia medicine amiodarone.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Merck & Co.
Abbott Laboratories
MORE ON THIS TOPIC
IPO
Electra lights up with $350M IPO for pivotal immune-disease drug development
September 18, 2026
·
1 min read
·
Gabrielle Masson
Neuropsychiatric disorders
Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity
September 18, 2026
·
4 min read
·
Annalee Armstrong
Cancer
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
September 18, 2026
·
1 min read
·
Tristan Manalac
Deals
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
September 17, 2026
·
2 min read
·
Michael Gibney